Patents by Inventor Anna TOMBERG

Anna TOMBERG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
    Patent number: 12729196
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: September 8, 2026
    Assignee: AstraZeneca AB
    Inventors: Jonas Brånalt, Björn Holm, Maria Johansson, Olle Karlsson, Daniel Laurent Knerr, Anneli Nordqvist, Robert John Sheppard, Marianne Swanson, Anna Tomberg
  • N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
    Publication number: 20260070899
    Abstract: Compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5, and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: June 20, 2023
    Publication date: March 12, 2026
    Inventors: Jonas BRÅNALT, Jakob DANIELSSON, Marlene FREDENWALL, Björn HOLM, Maria JOHANSSON, Anneli NORDQVIST, Marianne SWANSON, Anna TOMBERG, Susanne WINIWARTER
  • PCSK9 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240239767
    Abstract: A compound with the Formula (I): wherein A is of the following formula: and X1 is selected from O, S or NH; X2 is either N or C—H X3 is either N or C—RA3; wherein if X1 is NH and X2 is C—H then X3 is C—RA3; B is of formula (B-1) or (B-2) C is selected from the group consisting of optionally substituted C6-10 carboaryl, C5-6 heteroaryl or C5-10 heterocyclyl, and their use as PCSK9 inhibitors.
    Type: Application
    Filed: December 14, 2023
    Publication date: July 18, 2024
    Inventors: Gavin Donal O’MAHONY, Olaf PANKNIN, Andrey FROLOV, Anna TOMBERG, Mateusz Piotr PLESNIAK, Jens Peter BRANDT, Erik WEIS, Jens Patrik JOHANSSON, Emma BRATT
  • PCSK9 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240228469
    Abstract: A compound with the Formula (I): A-B-C??(I) wherein A is of the following formula: where X1 is N B is of formula (B-1) or (B-2) and C is selected from the group consisting of optionally substituted C6-10 carboaryl, C5-6 heteroaryl and C5-10 heterocyclyl and their use as PCSK9 inhibitors.
    Type: Application
    Filed: September 20, 2023
    Publication date: July 11, 2024
    Inventors: Gavin Donal O’MAHONY, Olaf PANKNIN, Andrey FROLOV, Anna TOMBERG, Erik WEIS, Hans Frederik BERGSTRÖM, Karl Thomas ANTONSSON, Jan Åke LINDBERG, Jens Patrik JOHANSSON
  • PCSK9 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240217951
    Abstract: A compound with the Formula (I): A-B—C??(I) wherein A is of the following formula: where X1 is C—RA1; B is of formula (B-1) or (B-2) and C is selected from the group consisting of optionally substituted C6-10 carboaryl, C5-6 heteroaryl and C5-10 heterocyclyl and their use as PCSK9 inhibitors.
    Type: Application
    Filed: September 20, 2023
    Publication date: July 4, 2024
    Inventors: Gavin Donal O’MAHONY, Olaf PANKNIN, Andrey FROLOV, Anna TOMBERG, Mateusz Piotr PLESNIAK, Jens Peter BRANDT, Jan Åke LINDBERG, Jens Patrik JOHANSSON
  • N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
    Publication number: 20240101549
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: December 16, 2021
    Publication date: March 28, 2024
    Inventors: Jonas BRÅNALT, Björn HOLM, Maria JOHANSSON, Olle KARLSSON, Daniel Laurent KNERR, Anneli NORDQVIST, Robert John SHEPPARD, Marianne SWANSON, Anna TOMBERG
  • N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
    Publication number: 20230312550
    Abstract: Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use of such compounds and salts to treat or prevent Prolyl endopeptidase fibroblast activation protein (FAP)-mediated conditions; kits comprising such compounds and salts; and methods for manufacturing such compounds and salts.
    Type: Application
    Filed: June 12, 2023
    Publication date: October 5, 2023
    Inventors: Jonas BRÅNALT, Björn HOLM, Maria JOHANSSON, Olle KARLSSON, Daniel Laurent KNERR, Anneli NORDQVIST, Robert John SHEPPARD, Marianne SWANSON, Anna TOMBERG